Potentiation by Tumor Necrosis Factor of Mitoxantrone Cytotoxicity to Human Ovarian Cancer Cell Lines

The cytotoxic activity of human recombinant tumor necrosis factor (rHuTNF) (from 0.01 to 10000 U/ml) was assayed on six human ovarian cancer cell lines and one human cervical carcinoma cell line using a crystal violet assay. rHuTNF was cytotoxic to four cell lines (A2780, A2774, SW626, PAD, while 3 cell lines (IGROV1, SKOV3, Mel80) were marginally sensitive to its activity. However, under the same experimental conditions rHuTNF markedly enhanced the cytotoxicity of mitoxantrone, a chemotherapeutic drug targeted at DNA topoisomerase II, in six cell lines. The potentiation of mitoxantrone cytotoxicity was not caused by increased drug accumulation after rHuTNF treatment. No significant increase in cytotoxicity to Me180 cell line was seen when rHuTNF was added to mitoxantrone.

[1]  S. Parodi,et al.  Synergistic cytotoxic effects of recombinant human tumor necrosis factor and Etoposide (VP16) or Doxorubicin on A2774 human epithelial ovarian cancer cell line , 1991, International Journal of Gynecologic Cancer.

[2]  S. Parodi,et al.  Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: potentiation of mitoxantrone cytotoxicity. , 1991, Gynecologic oncology.

[3]  G. Giaccone,et al.  Effects of tumor necrosis factor, alone or in combination with topoisomerase‐ii‐targeted drugs, on human lung cancer cell lines , 1990, International journal of cancer.

[4]  R. Bahnson,et al.  In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). , 1990, The Journal of urology.

[5]  M. Mattern,et al.  Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. , 1990, Cancer research.

[6]  F. Balkwill,et al.  Tumour necrosis factor as an anticancer agent. , 1990, European journal of cancer.

[7]  S. Rubin,et al.  Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Rosenberg,et al.  Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. , 1989, Cancer research.

[9]  C. Ware,et al.  Cytotoxicity mediated by tumor necrosis factor in variant subclones of the ME‐180 cervical carcinoma line: Modulation by specific inhibitors of DNA topoisomerase II , 1989, Journal of cellular biochemistry.

[10]  P. Walther,et al.  Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. , 1989, Archives of surgery.

[11]  S. Salmon,et al.  Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. S. Coffey,et al.  Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. , 1987, The Journal of urology.

[13]  D. S. Coffey,et al.  Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. , 1987, Cancer research.

[14]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.